Clinical profile of hospitalised moderate category COVID-19 patients: Short study from a Tertiary Care Centre in Delhi

Author:

Gautam Sachin1,Kumar Rahul1,Bhadoria Dharam Pal1,Mawari Govind2,Kumar Naresh3,Daga Mradul K.4,Pandit Sanjay1,Anuradha S.1,Pradhan Gaurav Shanker5,Garg Sandeep1,Sharma Gaurav1,Raghu RV1,Ritchie Nupur1,Jayamsulekha Dasari1

Affiliation:

1. Department of Internal Medicine, Maulana Azad Medical College, New Delhi, India

2. Department of Centre for Occupational and Environmental Health (COEH), Maulana Azad Medical College, New Delhi, India

3. Department of Pulmonary Medicine, Maulana Azad Medical College, New Delhi, India

4. Department of Internal Medicine and Infectious Disease, Institute of Liver and Biliary Sciences, New Delhi, India

5. Department of Radiodiagnosis, Maulana Azad Medical College, New Delhi, India

Abstract

Background: The clinical profile of hospitalized moderate-category COVID-19 patients has been understudied globally and in India. Aim: The present study was conducted to study the clinical profile and assess the proportions of patients who progressed to severe disease and its predictors among moderate COVID-19 patients. Materials and Methods: In this single-center observational study, 100 moderate-category COVID-19 patients as per Ministry of Health and Family Welfare (MoHFW) criteria of age ≥18 years of either sex, excluding pregnant females from February to November 2021, were studied by analyzing their clinical profiles and assessing Quick Sequential Organ Failure Assessment (qSOFA), National Early Warning Score 2 (NEWS-2), and chest computed-tomography severity score (CTSS) to predict progression to severe disease. Severe disease was defined as per MoHFW criteria. Results: Out of 100 moderate-category COVID-19 patients, progression to severe disease was seen in 11 patients (11%), among which eight patients had expired, three patients were discharged, and the rest of the 89 patients (89%) who did not progress to severe disease were discharged. A higher age (62.2± 19.5 vs 54.8 ± 14.6 years), along with multivariate analysis revealing male sex (1.25 times), chronic kidney disease (2.86 times), leukocytosis (6.10 times), thrombocytopenia (1.04 times), anemia (9.3 times), a higher qSOFA score (3.6 times), and a higher NEWS-2 score on admission (1.56 times) had higher odds of progression to severe disease. A significant correlation (P < .05) of qSOFA score with serum LDH, ferritin, and hs-CRP levels; CT severity score with the serum ferritin, IL-6, and LDH levels; and NEWS-2 with serum LDH, hs-CRP, and ferritin levels were found. Moreover, the NEWS-2 score was found slightly better than qSOFA on receiver operating characteristic (ROC) curve analysis, with an area under the curve of 85.8% and 83.2%, respectively, predicting progression to severe disease. Conclusion: Our study revealed male gender, chronic kidney disease, leukocytosis, anemia, thrombocytopenia, a higher qSOFA and NEWS-2 score on admission, and further, NEWS-2 score better than qSOFA on ROC curve analysis, with an area under the curve of 85.8% and 83.2%, respectively, in predicting severe disease among hospitalized moderate COVID-19 patients.

Publisher

Medknow

Subject

General Materials Science

Reference35 articles.

1. Evaluation of characteristics and outcomes of COVID-19 between first wave and second wave: Study from a tertiary cancer care centre, Delhi, India;Dogra;Cureus,2023

2. Mortality predictors in severe COVID-19 patients from an East European tertiary center: A never-ending challenge for a no happy ending pandemic;Timpau;J Clin Med,2021

3. Predictors of severity and mortality in COVID-19 patients;Assal;Egypt J Bronchol,2022

4. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review;Izcovich;PLoS One,2020

5. The Third International consensus definitions for sepsis and septic shock (Sepsis-3);Singer;JAMA,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3